Literature DB >> 2833614

Nucleotide sequences of cDNAs for human papillomavirus type 18 transcripts in HeLa cells.

Y Inagaki1, Y Tsunokawa, N Takebe, H Nawa, S Nakanishi, M Terada, T Sugimura.   

Abstract

HeLa cells expressed 3.4- and 1.6-kilobase (kb) transcripts of the integrated human papillomavirus (HPV) type 18 genome. Two types of cDNA clones representing each size of HPV type 18 transcript were isolated. Sequence analysis of these two types of cDNA clones revealed that the 3.4-kb transcript contained E6, E7, the 5' portion of E1, and human sequence and that the 1.6-kb transcript contained spliced and frameshifted E6 (E6*), E7, and human sequence. There was a common human sequence containing a poly(A) addition signal in the 3' end portions of both transcripts, indicating that they were transcribed from the HPV genome at the same integration site with different splicing. Furthermore, the 1.6-kb transcript contained both of the two viral TATA boxes upstream of E6, strongly indicating that a cellular promoter was used for its transcription.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2833614      PMCID: PMC253192          DOI: 10.1128/JVI.62.5.1640-1646.1988

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  High-efficiency cloning of full-length cDNA.

Authors:  H Okayama; P Berg
Journal:  Mol Cell Biol       Date:  1982-02       Impact factor: 4.272

2.  New M13 vectors for cloning.

Authors:  J Messing
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

Review 3.  Organization and expression of eucaryotic split genes coding for proteins.

Authors:  R Breathnach; P Chambon
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

Review 4.  Synthesis and processing of asparagine-linked oligosaccharides.

Authors:  S C Hubbard; R J Ivatt
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

5.  Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products.

Authors:  S T Cole; O Danos
Journal:  J Mol Biol       Date:  1987-02-20       Impact factor: 5.469

6.  Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose.

Authors:  H Aviv; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1972-06       Impact factor: 11.205

7.  Newly established uterine cervical cancer cell line (SKG-III) with Regan isoenzyme, human chorionic gonadotropin beta-subunit, and pregnancy-specific beta 1-glycoprotein phenotypes.

Authors:  S Nozawa; Y Udagawa; H Ohta; S Kurihara; W H Fishman
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions.

Authors:  M Dürst; L Gissmann; H Ikenberg; H zur Hausen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  21 in total

1.  Detection of transcripts of human papillomaviruses 16 and 18 in cancer-derived cell lines and cervical biopsies by enzyme immunoassay for DNA-RNA hybrids following solution hybridization.

Authors:  F Coutlée; K V Shah; J S Rader; J L Currie; R P Viscidi
Journal:  J Clin Microbiol       Date:  1991-05       Impact factor: 5.948

2.  Epigenetics of human papillomaviruses.

Authors:  Eric Johannsen; Paul F Lambert
Journal:  Virology       Date:  2013-08-13       Impact factor: 3.616

3.  Accumulation of p53 induced by the adenovirus E1A protein requires regions involved in the stimulation of DNA synthesis.

Authors:  E Querido; J G Teodoro; P E Branton
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

4.  Chemical synthesis of human papillomavirus type 16 E7 oncoprotein: autonomous protein domains for induction of cellular DNA synthesis and for trans activation.

Authors:  J A Rawls; R Pusztai; M Green
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

5.  The human papillomavirus type 18 (HPV18) E2 gene product is a repressor of the HPV18 regulatory region in human keratinocytes.

Authors:  B A Bernard; C Bailly; M C Lenoir; M Darmon; F Thierry; M Yaniv
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

6.  Characterization of a novel human papillomavirus DNA in the cervical carcinoma cell line ME180.

Authors:  S Reuter; H Delius; T Kahn; B Hofmann; H zur Hausen; E Schwarz
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

7.  Influence of chromosomal integration on glucocorticoid-regulated transcription of growth-stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells.

Authors:  M von Knebel Doeberitz; T Bauknecht; D Bartsch; H zur Hausen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

8.  Expression of LGI1 Impairs Proliferation and Survival of HeLa Cells.

Authors:  Nadia Gabellini; Valentina Masola
Journal:  Int J Cell Biol       Date:  2009-10-07

9.  Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions.

Authors:  M von Knebel Doeberitz; C Rittmüller; F Aengeneyndt; P Jansen-Dürr; D Spitkovsky
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

10.  Purification and characterization of human papillomavirus type 16 E7 protein with preferential binding capacity to the underphosphorylated form of retinoblastoma gene product.

Authors:  Y Imai; Y Matsushima; T Sugimura; M Terada
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.